What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
Ryerson Holding (NYSE: RYI) finalises Olympic Steel acquisition as North American metals consolidation accelerates
Read More 5 minute read Retail Industry News Rashi Peripherals (NSE: RPTECH) EBITDA rises in Q2 FY26 but PAT slips on ESOP cost: What does this mean for the stock’s outlook? Rashi Peripherals Q2 FY26 earnings show 12% revenue growth and 4% EBITDA rise. See how ESOP costs impacted PAT and what’s next for RPTECH. byPallavi MadhirajuNovember 8, 2025